DNP Assignment Help Samples — Doctoral-Level Writing Across All Components

What Doctoral-Level DNP Writing Looks Like

The samples below are anonymised extracts from DNP capstone deliverables produced at doctoral level. All identifying information — student names, clinical sites, universities, and faculty committee names — has been removed. The clinical specificity, AACN Essentials framing, EBP framework application, APA 7th formatting, and statistical precision shown here represent the standard our writers produce and the standard your committee expects.

Each extract is labelled by component type and specialisation track so you can find work that is closest to your own project context.

Sample PICOT Questions

A committee-ready PICOT question names all five elements explicitly in a single interrogative sentence. The population is specific (named setting, named diagnosis or demographic, not just "adult patients"). The intervention is a named protocol, not a vague activity. The outcome is measurable with a known baseline or benchmark. The time frame covers both implementation duration and the measurement window.

FNP Track — Hypertension Management: In adult patients aged 35 to 65 with uncontrolled hypertension (SBP ≥ 140 mmHg) enrolled in a Federally Qualified Health Centre primary care practice in the South-East United States, does implementation of a nurse-practitioner-led hypertension management protocol incorporating monthly BP monitoring, DASH diet counselling, and medication titration over 12 weeks, compared to usual care with quarterly physician visits, improve the percentage of patients achieving target BP control (SBP < 130 mmHg) from the current baseline of 41% to 65% or above by week 12 of the implementation period?

PMHNP Track — Medication Adherence: In adult patients aged 18 to 64 with a primary diagnosis of schizophrenia spectrum disorder (ICD-10: F20-F29) receiving outpatient psychiatric services at a community mental health centre in the Midwest, does implementation of a structured motivational interviewing-based medication adherence programme using the Morisky Medication Adherence Scale-8 (MMAS-8) for baseline and follow-up assessment over a 10-week implementation period, compared to standard medication management appointments without structured adherence education, improve the percentage of patients scoring in the high adherence category (MMAS-8 score ≥ 6) from the current baseline of 34% to 55% or above?

AGACNP Track — CAUTI Prevention: In adult patients with urinary catheters admitted to a 24-bed medical-surgical intensive care unit at a 450-bed Level II trauma centre, does implementation of a nurse-driven CAUTI prevention bundle incorporating daily catheter necessity assessment, standardised insertion and maintenance protocol, and weekly compliance audits over a 12-week implementation period, compared to the current practice without a structured daily necessity assessment process, reduce the CAUTI rate per 1,000 catheter days from the current 12-month baseline of 3.8 to at or below the NHSN national benchmark of 1.2?

CRNA Track — PONV Prevention: In adult patients aged 18 and older classified as Apfel Score 3 or 4 (high PONV risk) undergoing elective general anaesthesia at an ambulatory surgery centre in the Pacific Northwest, does implementation of a standardised multimodal PONV prophylaxis protocol incorporating ondansetron 4mg IV, dexamethasone 8mg IV, and scopolamine transdermal patch applied pre-operatively over a 10-week implementation period, compared to the current practice of single-agent prophylaxis at anaesthesia provider discretion, reduce the incidence of PONV in the post-anaesthesia care unit from the current baseline of 28% to 12% or below?

Sample Problem Statement — Chapter 1 (AGACNP Track)

The following extract is from Chapter 1, Background of the Problem section. Note the local quantified baseline, the NHSN benchmark comparison, and the specific compliance gap identified from unit-level quality data — the three elements that distinguish a committee-ready problem statement from a generic background paragraph.

At [clinical site], a 24-bed mixed medical-surgical intensive care unit within a 450-bed Level II trauma centre in the Southeastern United States, the catheter-associated urinary tract infection (CAUTI) rate per 1,000 catheter days was 3.8 in the most recent 12-month NHSN reporting period (January through December 2024), a rate that exceeds both the NHSN national benchmark of 1.2 per 1,000 catheter days (CDC, 2024) and the facility's internal quality target of 2.0 per 1,000 catheter days established by the Quality Improvement Department in 2022. A unit-specific process audit conducted by the infection control nurse in October 2024 documented that daily catheter necessity assessment — a core element of evidence-based CAUTI prevention bundles (Gould et al., 2017; Saint et al., 2016) — was completed on only 42% of eligible patient-catheter days reviewed. The gap between the established evidence base for CAUTI prevention and the current implementation fidelity at [clinical site] identifies a practice problem that is amenable to a quality improvement intervention targeting nurse-driven daily necessity assessment.

Sample Evidence Synthesis Paragraph — Chapter 2 (FNP Track)

The following extract is from the evidence synthesis narrative in Chapter 2. It demonstrates thematic synthesis across multiple studies — not a study-by-study summary — followed by a GRADE-informed certainty statement and a practice gap sentence connecting the literature to the local context.

Across the 22 studies included in this review, two consistent themes emerged: nurse-practitioner-led hypertension management protocols produced statistically significant improvements in BP control rates compared to usual physician-only care, and structured patient self-monitoring education produced additional BP reductions of 4 to 7 mmHg SBP above medication titration alone. Eight of the nine RCTs included in this review reported between-group differences in BP control rates that exceeded the Minimal Clinically Important Difference of 5 mmHg SBP (Rabi et al., 2020), with pooled effect sizes ranging from Cohen's d = 0.42 to d = 0.71 across study populations. The overall certainty of evidence across included RCTs was rated as moderate using the GRADE framework (Guyatt et al., 2011), with downgrading applied for inconsistency in the definition of BP control threshold across studies (SBP < 130 mmHg in five studies vs SBP < 140 mmHg in four studies) and for single-site designs in three high-effect-size studies that limit external validity. No studies identified in this review were conducted in FQHC primary care settings with predominantly Medicaid-enrolled patient populations, a gap in the evidence base that the proposed quality improvement project at [clinical site] directly addresses.

Sample Statistical Analysis Plan — Chapter 3

The following extract is from Chapter 3, Data Analysis section. This is the section most commonly returned by committees for revision — committees expect named tests, named software, stated significance levels, and a non-parametric alternative plan. Vague language ("appropriate statistical analysis will be used") fails committee review.

Pre-implementation and post-implementation CAUTI rates per 1,000 catheter days will be compared using a paired t-test (two-tailed, alpha = 0.05) after confirming the assumption of normality using the Shapiro-Wilk test (p > 0.05 interpreted as no significant deviation from normality). If the Shapiro-Wilk test indicates a violation of normality (p ≤ 0.05), the Wilcoxon signed-rank test will be used as the non-parametric alternative. Both tests will be performed in JASP (version 0.18.3; JASP Team, 2024). Weekly CAUTI prevention bundle compliance rates (percentage of eligible catheter-days with documentation of all five bundle elements completed) will be displayed as a statistical process control P-chart with upper and lower control limits calculated at three standard deviations from the mean compliance rate. A run of eight or more consecutive data points above or below the centreline, or any data point outside the three-sigma control limits, will be interpreted as evidence of a special cause signal indicating a non-random shift in the process. Clinical significance will be evaluated by comparing the post-implementation CAUTI rate to the NHSN national ICU benchmark of 1.2 per 1,000 catheter days (CDC, 2024), independent of the inferential test result, because sample size constraints typical of single-unit QI projects may limit statistical power to detect clinically meaningful differences (Melnyk & Fineout-Overholt, 2023).

Sample Discussion Section Extract — Final Manuscript (PMHNP Track)

The following is from the Discussion section of a final DNP manuscript. Note the structure: restate primary finding, interpret against the MCID, compare to named studies, apply the theoretical framework, and address the null/unexpected finding in the secondary outcome.

The primary outcome of this quality improvement project was a statistically significant improvement in the percentage of patients classified as high adherence on the MMAS-8 (score ≥ 6), from a baseline of 34% to 61% at 10 weeks post-implementation (McNemar test, p = 0.003), a change that exceeds the MMAS-8 clinically meaningful threshold of a 20-percentage-point improvement in the high-adherence category established by Morisky et al. (2008). This finding is consistent with two RCTs included in the evidence synthesis: Staring et al. (2010) reported a 19-percentage-point improvement in high-adherence classification following a six-session motivational interviewing intervention in outpatient schizophrenia populations (p = 0.01), and Gray et al. (2016) reported a 23-percentage-point improvement in a community mental health centre setting comparable to the project site (p = 0.008). The results support the theoretical premise of the Iowa Model of EBP (Titler et al., 2001) as applied to this project: the structured trigger identification stage (MMAS-8 baseline assessment) enabled the care team to identify modifiable adherence barriers before designing the educational intervention, increasing the likelihood that the intervention addressed the specific deficits present in this patient population rather than applying a generic psychoeducation protocol. The secondary outcome — 30-day psychiatric hospitalisation rate — did not show a statistically significant reduction at the 10-week measurement point (14% pre-implementation vs 11% post-implementation; McNemar test, p = 0.31), a null finding that is consistent with the project's short implementation window and the known 60 to 90 day lag between medication adherence improvement and measurable reduction in hospitalisation risk reported by Ascher-Svanum et al. (2006).